Whistleblower vows to fight onBMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7433.187-c (Published 22 January 2004) Cite this as: BMJ 2004;328:187
- Clare Dyer, legal correspondent
A Canadian haematologist at the centre of a cause célèbre over academic freedom and research funded by a drug company vowed this week to continue her crusade after failing in her attempt to challenge the European marketing authorisation granted for the thalassaemia drug deferiprone.
Nancy Olivieri, professor of paediatrics and medicine at the University of Toronto, asked the European court of justice in Luxembourg to suspend the authorisation granted by the committee for proprietary and medicinal products (CPMP), the drug licensing body for the European Union.
Dr Olivieri, a specialist in thalassaemia, had been conducting trials on the drug in young patients when she broke a confidentiality agreement with Apotex, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial